Abstract
This book collects salient observational data, derived predominantly from human studies, regarding the mechanism(s) of rejection in various pathologic conditions; the premise is that immune rejection, better defined as “immune-mediated, tissue-specific destruction” (TSD) (Wang et al. 2008), comprises a broad range of phenomena ranging from tumor regression, to clearance of pathogen through destruction of infected cells, autoimmunity, allograft rejection by the host and host vs. graft reactions. Like different hands can turn on or off a switch, distinct mechanisms can trigger TSD, however, a convergent pathway is ultimately observed when TSD occurs consisting of a dramatic switch from chronic to acute inflammation (Mantovani et al. 2008).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Asselah T, Bieche I, Narguet S et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57(4):516–524.
Benencia F, Courreges MC, Conejo-Garcia JR et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005; 12(5):789–802.
Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001; 75(15):7059–7066.
Camus M, Tosolini M, Mlecnik B et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009; 69(6):2685–2693.
Costa C, Rufino R, Traves SL, Lapa E Silva JR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008; 133(1):26–33.
Dieu-Nosjean MC, Antoine M, Danel C et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26(27):4410–4417.
Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46(5):1548–1563.
Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313(5795):1960–1964.
Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67(5):1883–1886.
Hardstedt M, Finnegan CP, Kirchhof N et al. Post-transplant upregulation of chemokine messenger RNA in non-human primate recipients of intraportal pig islet xenografts. Xenotransplantation 2005; 12(4):293–302.
Harlin H, Meng Y, Peterson AC et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69(7):3077–3085.
He XS, Ji X, Hale MB et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 2006; 44(2):352–359.
Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6(9):644–658.
Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25(3):349–360.
Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009; 113(15):3620–3630.
Jin P, Wang E, Provenzano M, Stroncek D, Marincola FM. Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. Crit Rev Immunol 2007; 27(5):437–448.
Karason K, Jernas M, Hagg DA, Svensson PA. Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection. BMC Cardiovasc Disord 2006; 6:29.
Lee JH, Chun T, Park SY, Rho SB. Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs. Biochim Biophys Acta 2008; 1783(9):1654–1662.
Mantovani A, Romero P, Palucka AK, Marincola FM. Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 2008; 371(9614):771–783.
Nanda S, Havert MB, Calderon GM et al. Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS ONE 2008; 3(10):e3442.
Okamoto Y, Folco EJ, Minami M et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008; 102(2):218–225.
Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353(25):2654–2666.
Panelli MC, Wang E, Phan G et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002; 3(7):RESEARCH0035.
Panelli MC, Stashower M, Slade HB et al. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2006; 8(1):R8.
Paun A, Pitha PM. The IRF family, revisited. Biochimie 2007; 89(6–7):744–753.
Reeve J, Einecke G, Mengel M et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9(8):1802–1810.
Saint-Mezard P, Berthier CC, Zhang H et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int 2009; 22(3):293–302.
Salk J. Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. Ann N Y Acad Sci 1969; 164(2):365–380.
Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349(2):125–138.
Shanker A, Verdeil G, Buferne M et al. CD8 T cell help for innate antitumor immunity. J Immunol 2007; 179(10):6651–6662.
Taniguchi T. Transcription factors IRF-1 and IRF-2: linking the immune responses and tumor suppression. J Cell Physiol 1997; 173(2):128–130.
Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. Irf family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19:623–655.
Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62:3581–3586.
Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008; 29(6):256–262.
Worschech A, Chen N, Yu YA et al. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facets of oncolytic therapy. BMC Genomics 2009; 10:301.
Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002; 169(3):1556–1560.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Wang, E., Marincola, F.M. (2011). From the “Delayed Allergy Reaction” to the “Immunologic Constant of Rejection”. In: Marincola, F., Wang, E. (eds) Immunologic Signatures of Rejection. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7219-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7219-4_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7218-7
Online ISBN: 978-1-4419-7219-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)